Patent · US Active

Formulation for inhibiting formation of 5-HT2B agonists and methods of using same

US10603290B2 · kind B2 · utility

10Cited by

9References

10Claims

0Family size

Assignee

Zogenix International Limited · GB

Inventors

Stephen J. Farr · Orinda, US
Brooks Boyd · Berkeley, US

Key dates

Filing date	Nov 16, 2018
Grant date	Mar 31, 2020
Priority date	—
Expiry date	Nov 16, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.